Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
出版年份 2018 全文链接
标题
Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
作者
关键词
HGF/c-Met, PI3K/AKT, Ras/MAPK, Wnt, RON, EGFR, Therapeutic strategy
出版物
Molecular Cancer
Volume 17, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-02-15
DOI
10.1186/s12943-018-0796-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma
- (2017) Ignace B. Vergote et al. EUROPEAN JOURNAL OF CANCER
- Tivantinib for the treatment of hepatocellular carcinoma
- (2017) Jan Best et al. EXPERT OPINION ON PHARMACOTHERAPY
- C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives
- (2017) Afsane Bahrami et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Intracranial Activity of Cabozantinib in MET Exon 14–Positive NSCLC with Brain Metastases
- (2017) Samuel J. Klempner et al. Journal of Thoracic Oncology
- Role of long non-coding RNAs in glucose metabolism in cancer
- (2017) Chunmei Fan et al. Molecular Cancer
- Circular RNAs in human cancer
- (2017) Yumin Wang et al. Molecular Cancer
- Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment
- (2017) Agnieszka A. Rucki et al. MOLECULAR CANCER THERAPEUTICS
- MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale
- (2017) Ravi Salgia MOLECULAR CANCER THERAPEUTICS
- Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma
- (2017) Hanyin Cheng et al. MOLECULAR CANCER THERAPEUTICS
- RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells
- (2017) Binbin Yin et al. ONCOLOGY REPORTS
- The c-Met receptor: Implication for targeted therapies in colorectal cancer
- (2017) Elmira Safaie Qamsari et al. TUMOR BIOLOGY
- The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells
- (2017) Terumichi Shintani et al. UROLOGY
- Anti-c-Met antibody bioconjugated with hollow gold nanospheres as a novel nanomaterial for targeted radiation ablation of human cervical cancer cell
- (2017) Ying Liang et al. Oncology Letters
- MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor
- (2017) Sean Caenepeel et al. Oncotarget
- Role of tumor microenvironment in tumorigenesis
- (2017) Maonan Wang et al. Journal of Cancer
- Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
- (2017) Aryan Stanley et al. Scientific Reports
- Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma
- (2016) Yoshinori Imura et al. CANCER SCIENCE
- Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53
- (2016) Wen-Ting Liu et al. CELL CYCLE
- c-Met inhibition enhances chemosensitivity of human ovarian cancer cells
- (2016) Jing Wang et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Cabozantinib for the treatment of renal cell carcinoma
- (2016) Bernard Escudier et al. EXPERT OPINION ON PHARMACOTHERAPY
- Interaction between Wnt/β-catenin pathway and microRNAs regulates epithelial-mesenchymal transition in gastric cancer (Review)
- (2016) CUNEN WU et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Acid sphingomyelinase is required for cell surface presentation of Met receptor tyrosine kinase in cancer cells
- (2016) Linyu Zhu et al. JOURNAL OF CELL SCIENCE
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
- (2016) Paul E. Hughes et al. MOLECULAR CANCER THERAPEUTICS
- Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma
- (2016) Samarpita Barat et al. MOLECULAR CARCINOGENESIS
- Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
- (2016) NATURE MEDICINE
- Blood vessel endothelium-directed tumor cell streaming in breast tumors requires the HGF/C-Met signaling pathway
- (2016) E Leung et al. ONCOGENE
- Apigenin Inhibits Cancer Stem Cell-Like Phenotypes in Human Glioblastoma Cells via Suppression of c-Met Signaling
- (2016) Boram Kim et al. PHYTOTHERAPY RESEARCH
- Heteronemin Is a Novel c-Met/STAT3 Inhibitor Against Advanced Prostate Cancer Cells
- (2016) Jian-Ching Wu et al. PROSTATE
- Beta 1-integrin–c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes
- (2016) Rachel Barrow-McGee et al. Nature Communications
- A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
- (2015) H. Yoshioka et al. ANNALS OF ONCOLOGY
- Effects of Exercise on Tumor Physiology and Metabolism
- (2015) Line Pedersen et al. CANCER JOURNAL
- Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors
- (2015) Takuji Okusaka et al. CANCER SCIENCE
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma
- (2015) Qingfeng Xiang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches
- (2015) Meghan Shea et al. Therapeutic Advances in Respiratory Disease
- HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer
- (2015) Marisa Mariani et al. Oncotarget
- Ron Receptor Tyrosine Kinase Activation Confers Resistance to Tamoxifen in Breast Cancer Cell Lines
- (2015) Rebecca J. McClaine et al. NEOPLASIA
- Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
- (2014) Igor Puzanov et al. INVESTIGATIONAL NEW DRUGS
- EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells
- (2014) Kiran Kumar Velpula et al. Translational Oncology
- EGF Receptor Activates MET through MAPK to Enhance Non-Small Cell Lung Carcinoma Invasion and Brain Metastasis
- (2013) J. L. Breindel et al. CANCER RESEARCH
- Targeting the MET gene for the treatment of non-small-cell lung cancer
- (2013) F. Gelsomino et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The Wnt/β-catenin pathway in ovarian cancer: A review
- (2013) Rebecca C. Arend et al. GYNECOLOGIC ONCOLOGY
- Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
- (2013) Manish A. Shah et al. PLoS One
- Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
- (2013) M. Merchant et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
- (2013) Frauke Bentzien et al. THYROID
- Combined Wnt/β-Catenin, Met, and CXCL12/CXCR4 Signals Characterize Basal Breast Cancer and Predict Disease Outcome
- (2013) Jane D. Holland et al. Cell Reports
- Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines
- (2013) S Zhao et al. Oncogenesis
- Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer
- (2012) W. Wang et al. CLINICAL CANCER RESEARCH
- Targeting the HGF/Met signaling pathway in cancer therapy
- (2012) Fabiola Cecchi et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
- (2012) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells
- (2012) Kang Ho Kim et al. NEURO-ONCOLOGY
- Lung cancer: New biological insights and recent therapeutic advances
- (2011) Suresh S. Ramalingam et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ron Kinase Transphosphorylation Sustains MET Oncogene Addiction
- (2011) S. Benvenuti et al. CANCER RESEARCH
- A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma
- (2011) Hanning You et al. HEPATOLOGY
- Distinct Involvement of the Gab1 and Grb2 Adaptor Proteins in Signal Transduction by the Related Receptor Tyrosine Kinases RON and MET
- (2011) Amitabha Chaudhuri et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast Cancer-Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown
- (2011) S. Previdi et al. MOLECULAR CANCER THERAPEUTICS
- Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis
- (2010) Elisa Benedettini et al. AMERICAN JOURNAL OF PATHOLOGY
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Silencing of RON Receptor Signaling Promotes Apoptosis and Gemcitabine Sensitivity in Pancreatic Cancers
- (2010) J. Logan-Collins et al. CANCER RESEARCH
- Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency
- (2010) U. McDermott et al. CANCER RESEARCH
- Targeting the HGF/Met signalling pathway in cancer
- (2010) Fabiola Cecchi et al. EUROPEAN JOURNAL OF CANCER
- Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and β-catenin/Wnt pathways
- (2010) Sara Previdi et al. EUROPEAN JOURNAL OF CANCER
- Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
- (2009) S Agarwal et al. BRITISH JOURNAL OF CANCER
- Cyclooxygenase-2 Inhibition Inhibits c-Met Kinase Activity and Wnt Activity in Colon Cancer
- (2008) J. B. Tuynman et al. CANCER RESEARCH
- Met and c-Src Cooperate to Compensate for Loss of Epidermal Growth Factor Receptor Kinase Activity in Breast Cancer Cells
- (2008) K. L. Mueller et al. CANCER RESEARCH
- AKT Signaling in Regulating Angiogenesis
- (2008) Bing-Hua Jiang et al. CURRENT CANCER DRUG TARGETS
- Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma
- (2008) Ai-Wu Ke et al. HEPATOLOGY
- Smad4-dependent TGF-β Signaling Suppresses RON Receptor Tyrosine Kinase-dependent Motility and Invasion of Pancreatic Cancer Cells
- (2008) Shujie Zhao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
- (2008) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Re: Prognostic Value of MET, RON and Histoprognostic Factors for Urothelial Carcinoma in the Upper Urinary Tract
- (2008) Jay D. Raman JOURNAL OF UROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started